HUTCHMED (LON:HCM) Stock Price Passes Below Two Hundred Day Moving Average of $229.43

HUTCHMED (China) Limited (LON:HCMGet Rating) shares crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 229.43 ($2.77) and traded as low as GBX 212 ($2.56). HUTCHMED shares last traded at GBX 223 ($2.69), with a volume of 121,234 shares.

Analyst Upgrades and Downgrades

HCM has been the subject of several recent research reports. Citigroup reiterated a “buy” rating and set a GBX 220 ($2.66) target price on shares of HUTCHMED in a research note on Thursday, June 23rd. Barclays reiterated an “equal weight” rating and set a GBX 100 ($1.21) target price on shares of HUTCHMED in a research note on Tuesday, July 19th.

HUTCHMED Stock Performance

The company has a debt-to-equity ratio of 0.05, a current ratio of 3.18 and a quick ratio of 2.97. The stock has a market cap of ¬£1.93 billion and a price-to-earnings ratio of -11.09. The stock’s 50-day moving average is GBX 219.72 and its 200 day moving average is GBX 229.43.

About HUTCHMED

(Get Rating)

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.

Featured Articles

Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.